Vaxcyte, Inc.
825 Industrial Road
Suite 300
San Carlos, CA 94070
United States
650 837 0111
https://vaxcyte.com
版塊: Healthcare
行業: Biotechnology
全職員工: 254
高階主管
| 名稱 | 頭銜 | 支付 | 行使價 | 出生年份 |
|---|---|---|---|---|
| Mr. Grant E. Pickering M.B.A. | Co-Founder, CEO & Director | 1.06M | 1.12M | 1968 |
| Mr. Andrew L. Guggenhime M.B.A. | President & CFO | 765k | 1.77M | 1968 |
| Mr. James Wassil M.B.A., M.S. | Executive VP & COO | 485.62k | 879.45k | 1969 |
| Mr. Mikhail Eydelman J.D. | Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary | 638.06k | 867.35k | 1982 |
| Dr. Ashish Khanna M.B.A., Ph.D. | Co-Founder | 無 | 無 | 1972 |
| Dr. Jeff Fairman Ph.D. | Co-Founder & VP of Research | 無 | 無 | 1964 |
| Ms. Elvia Cowan | Senior VP of Finance & Principal Accounting Officer | 無 | 無 | 1973 |
| Ms. Janet Graesser | Senior Vice President of Corporate Communications & Investor Relations | 無 | 無 | 無 |
| Ms. Whitney Jones | Chief People Officer | 無 | 無 | 無 |
| Mr. Paul W. Sauer M.B.A. | Senior Vice President of Process Development & Manufacturing | 567.55k | 無 | 1961 |
描述
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
公司管治
截至 2024年5月1日 止，Vaxcyte, Inc. 的 ISS 管治質素評分為 7。 Pillar 分數正在審核中：3；董事會：4；股東權利：8；現金賠償：9。
